Study 1 of 1 for search of: nct00509977
Previous Study Return to Search Results Next Study

Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Light Treatment and Laser Treatment for Melasma
This study is ongoing, but not recruiting participants.
First Received: July 31, 2007   Last Updated: November 19, 2009   History of Changes
Sponsor: Northwestern University
Information provided by: Northwestern University
ClinicalTrials.gov Identifier: NCT00509977
  Purpose

The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.


Condition Intervention
Melasma
Procedure: Light Treatment
Procedure: Laser Treatment

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Study of Light Treatment and Laser Treatment for Melasma

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Melasma Area and Severity Index [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety [ Time Frame: 20 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: April 2007
Estimated Study Completion Date: June 2010
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Light therapy
Procedure: Light Treatment
Light treatment applied to half of the face at each study visit
2: Experimental
Laser Treatment
Procedure: Laser Treatment
Laser treatment applied to half of the face at each study visit

Detailed Description:

The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of melasma lesion measuring at least 4 square centimeters.
  • Age 18-75 years.
  • Good health.
  • Willingness and ability to understand and provide informed consent for participation in the study.
  • Ability to communicate with the investigator.
  • Must be willing to forgo other treatment options for melasma during the course of the study.

Exclusion Criteria:

  • Inability to understand the protocol or to give informed consent.
  • Mental illness.
  • Under 18 years of age and over 75 years of age.
  • Laser treatment in the last 6 months before enrollment.
  • Isotretinoin within the past year.
  • Lidocaine allergy.
  • History of herpes simplex viral infection.
  • Concurrent active disease to facial area (i.e acne).
  • Bleeding disorder.
  • History of abnormal wound healing.
  • History of abnormal scarring.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00509977

Locations
United States, Illinois
Northwestern University Dermatology Department
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Investigators
Principal Investigator: Murad Alam, MD Northwestern University
  More Information

No publications provided by Northwestern University

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Responsible Party: Murad Alam, MD ( Northwestern University )
Study ID Numbers: MA-12345-DD
Study First Received: July 31, 2007
Last Updated: November 19, 2009
ClinicalTrials.gov Identifier: NCT00509977     History of Changes
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hyperpigmentation
Skin Diseases
Pigmentation Disorders
Melanosis

ClinicalTrials.gov processed this record on February 04, 2010